Document Detail


Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
MedLine Citation:
PMID:  19422478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: To evaluate, in clinical practice, the efficacy and safety of combined antiviral treatment in hepatitis C virus (HCV) carriers with normal alanine aminotransferase (ALT) levels. METHODS: Eighty-eight HCV carriers with persistently normal ALT levels were enrolled. All patients received peginterferon (PEG-IFN) alpha-2a 180 microg once weekly plus ribavirin (RBV) 800 mg/day for 24 weeks (HCV-2 and -3) or 1000-1200 mg/day for 48 weeks (HCV-1). RESULTS: Rapid virological response (RVR) was seen in 66/88 patients (75%): 19/32 HCV-1 (59%), 40/46 HCV-2 (87%) and 7/10 HCV-3 patients. Younger patients, leaner subjects and patients with non-1 genotype or lower baseline HCV RNA levels were more likely to achieve an RVR. Sustained virological response (SVR) was seen in 69/88 patients (78%): 20/32 HCV-1 patients (62%), 41/46 HCV-2 patients (89%) and 8/10 (80%) HCV-3 patients. The overall SVR rate was 88% in patients with RVR (58/66) and 50% in those without RVR. CONCLUSIONS: The combination of PEG-IFN alpha-2a and RBV produces, in patients with normal ALT, virological response rates that are comparable or even higher than those obtained in patients with elevated ALT levels. Thus, we suggest that in selected cases immediate therapy might be preferred to a 'wait-and-see' policy.
Authors:
Claudio Puoti; Adriano M Pellicelli; Mario Romano; Fabrizio Mecenate; Riccardo Guarisco; Giorgio Barbarini; Ettore Mazzoni; Lucia Spilabotti; Lia Bellis; Federica Paglia; Angelo Barlattani; Antonio Picardi; Amerigo Paffetti; Maria Elena Bonaventura; Lorenzo Nosotti; Olga Mitidieri; Orlando Dell'Unto; Roberto Villani; Chiara Dell'Unto; Aldo Morrone; Fabrizio Soccorsi;
Related Documents :
16400348 - Osteoporosis in liver cirrhosis.
9346568 - Acute liver failure: results of a 5-year clinical protocol.
20943458 - Expression level of augmenter of liver regeneration in patients with hepatic failure an...
21033238 - The impact of steatosis on liver stiffness measurement in patients with chronic hepatit...
1633048 - Air enema revisited in assessment of colitis.
23689678 - Hemolacria in a patient with severe systemic diseases.
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2009-04-28
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  29     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-08     Completed Date:  2010-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  1479-84     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine and Liver Unit, Marino Hospital, Rome, Italy. puoti@epatologia.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine Transaminase / blood*
Antiviral Agents / administration & dosage*
Carrier State / drug therapy*,  pathology,  virology
Drug Therapy, Combination
Female
Hepatitis C / drug therapy*,  pathology,  virology
Humans
Interferon Alfa-2a / administration & dosage*
Liver / pathology
Male
Middle Aged
Polyethylene Glycols / administration & dosage*
RNA, Viral / blood
Ribavirin / administration & dosage*
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcino...
Next Document:  Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patient...